Drug Profile
Research programme: cardiac ion channel modulators - AnaBios/Sanofi
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Sanofi
- Developer AnaBios Corporation; Sanofi
- Class Antiarrhythmics
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Atrial-fibrillation in USA
- 08 Feb 2018 AnaBios Corporation acquires development and commercialisation rights to an undisclosed family of Atrial fibrillation compounds from Sanofi
- 08 Feb 2018 Preclinical trials in Atrial fibrillation in USA (unspecified route) (9233193; AnaBios Corporation website, February 2018)